Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study.

ABSTRACT:

Objective

To assess whether abatacept as initial biological DMARD (bDMARD) in the treatment of RA, when compared with other bDMARDs, is associated with an increased risk of cancer overall and by specific cancer sites (breast, lung, lymphoma, melanoma and non-melanoma skin cancer).

Methods

We performed a population-based cohort study among patients newly treated with bDMARDs within the US-based Truven MarketScan population and Supplemental US Medicare from 2007 to 2014. Cox proportional hazards models were used to estimate hazard ratios and 95% CIs of any cancer (and specific cancers) associated with initiation of abatacept, compared with initiation of other bDMARDs, adjusted for age and deciles of the propensity score.

Results

The cohort included 4328 patients on abat

SUBMITTER: Montastruc F 

PROVIDER: S-EPMC6434371 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature